“A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients With High-Risk Cutaneous Squamous Cell Carcinoma (cSCC)”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, pp. 482-96, https://doi.org/10.25251/skin.6.6.5.